Investigative radiology
-
Investigative radiology · May 2013
Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
The aim of this pilot study was to demonstrate the potential of simultaneously acquired 68-Gallium-DOTA-D-Phe1-Tyr3-octreotide (68Ga-DOTATOC) positron emission tomography/magnetic resonance imaging (PET/MRI) in comparison with 68Ga-DOTATOC PET/computed tomography (PET/CT) in patients with known gastroenteropancreatic neuroendocrine tumors (NETs). ⋯ This pilot study demonstrates the potential of 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic NET, with special advantages in the characterization of abdominal lesions yet certain weaknesses inherent to MRI, such as lung metastases and hypersclerotic bone lesions.
-
Investigative radiology · May 2013
Comparative StudyEvaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
The primary aims of this study were to evaluate the feasibility of simultaneous 68(DOTA(0)-Phe(1)-Tyr(3))octreotide positron emission tomography (PET)/magnetic resonance (MR) acquisition on a fully integrated PET/MR scanner in patients and to compare the quality of PET images acquired with a PET/MR device with those acquired with a PET/computed tomography (CT) scanner. ⋯ 68Ga-DOTATOC PET/MR imaging is feasible in patients, with good image quality, and detectability of focal PET lesions was equivalent to PET/CT on a patient basis and organ system basis. Now, the clinical value of 68Ga-DOTATOC PET/MR with additional diagnostic MR protocols has to be evaluated against PET/CT with multiphase contrast-enhanced CT protocols in future studies.
-
Investigative radiology · May 2013
Comparative StudyPreclinical evaluation of MR attenuation correction versus CT attenuation correction on a sequential whole-body MR/PET scanner.
The application of attenuation correction for combined magnetic resonance/positron emission tomography (MR/PET) systems is still a major challenge for accurate quantitative PET. Computed tomographic attenuation correction (CTAC) is the current clinical standard for PET/computed tomographic (CT) scans. Magnetic resonance, unlike CT, has no direct information about photon attenuation but, rather, proton densities. On combined MR/PET scanners, MR-based attenuation correction (MRAC) consists of assigning empirical attenuation coefficients to MR signal intensities. The objective of the current study was to evaluate the MRAC implemented on the combined MR/PET scanner versus the CTAC with the same PET data in an animal model. ⋯ In this study, we have compared MRAC and CTAC methods for PET attenuation correction in an animal model. We have confirmed that the MRAC method implemented on a sequential MR/PET scanner underestimates PET values by less than 10% in most regions, except the areas containing or close to large bone structures such as the spine or the back muscles. Bone segmentation is therefore suggested to be included in the MR attenuation map to minimize the quantification error of MRAC methods compared with the clinical standard CTAC. Further clinical studies need to be carried out to validate the clinical use of MRAC.
-
Investigative radiology · May 2013
Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Hybrid whole-body magnetic resonance/positron emission tomography (MR/PET) systems are a new diagnostic tool enabling the simultaneous acquisition of morphologic and multiple functional data and thus allowing for a diversified characterization of oncological diseases.The aim of this study was to investigate the image and alignment quality of MR/PET in patients with pulmonary lesions and to compare the congruency of the 2 functional measurements of diffusion-weighted imaging (DWI) in MR imaging and 2-deoxy-[18F] fluoro-2-D-glucose (FDG) uptake in PET. ⋯ Examinations of pulmonary lesions in a simultaneous whole-body MR/PET system provide diagnostic image quality in both modalities. Although DWI and FDG-PET reflect different tissue properties, there may very well be an association between the measures of both methods most probably because of increased cellularity and glucose metabolism of FDG-avid pulmonary lesions. A voxelwise DWI and FDG-PET correlation might provide a more sophisticated spatial characterization of pulmonary lesions.
-
Investigative radiology · May 2013
Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps.
Attenuation correction of positron emission tomographic (PET) data is critical in providing accurate and quantitative PET volumes. Deriving an attenuation map (μ-map) from magnetic resonance (MR) volumes is a challenge in PET/MR hybrid imaging. The difficulty lies in differentiating cortical bone from air from standard MR sequences because both these classes yield little to no MR signal and thus shows no distinguishable information. The objective of this contribution is 2-fold: (1) to generate and evaluate a continuous valued computed tomography (CT)-like attenuation map (μ-map) with continuous density values from dedicated MR sequences and (2) to compare its PET quantification accuracy with respect to a CT-based attenuation map as the criterion standard and other segmentation-based attenuation maps for studies of the head. ⋯ In this study, the generation of continuous valued attenuation maps from MR sequences is demonstrated and its effect on PET quantification is evaluated in comparison with segmentation-based μ-maps. A less-than-2-minute acquisition time makes the proposed approach promising for a clinical application for studies of the head. However, further experiments are required to validate and evaluate this technique for attenuation correction in other regions of the body.